Asundexian's Phase 3 study results raise hopes for a new class of cardiovascular drugs that has seen clinical setbacks.

The studies offer perhaps the most concrete rebuttal yet to an idea that GLP-1 drugs, which have profound benefits on weight ...

Newly launched Dayra Therapeutics has agreed to identify for Biogen "oral macrocycle candidates" that go after "high-priority ...

It’s well known that AD has a strong genetic component. Apolipoprotein E (APOE4) is expressed in 40% to 65% of all AD ...

The pharmaceutical company’s success developing medicines for obesity has swelled its worth to levels associated with tech ...

The clearance of Redemplo for a rare genetic disorder marks Arrowhead’s transition, after two decades, into a ...

The agency is evaluating whether further regulatory action is warranted after receiving reports of neutralizing antibodies.

Pyrukynd, which Agios sells for a rare type of anemia, missed one of its main objectives in a study seen as crucial for its ...

The purchase would give Abbott access to cancer screening tests including Cologuard and blood tests for multi-cancer early ...

Shares of Contineum Therapeutics dipped by the double-digits late Thursday after investors learned of a clinical setback for ...

The cell therapy maker said Thursday the raise will support an ongoing trial of its experimental treatment for the ...

Winrevair, which Merck has identified as a “growth driver,” significantly improved blood flow through the lungs to the heart ...